Nuvectis Pharma Statistics
Total Valuation
Nuvectis Pharma has a market cap or net worth of $767.62 million. The enterprise value is $745.46 million.
| Market Cap | 767.62M |
| Enterprise Value | 745.46M |
Important Dates
The last earnings date was Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvectis Pharma has 32.58 million shares outstanding. The number of shares has increased by 21.66% in one year.
| Current Share Class | 32.58M |
| Shares Outstanding | 32.58M |
| Shares Change (YoY) | +21.66% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 34.92% |
| Owned by Institutions (%) | 33.57% |
| Float | 21.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 69.25 |
| P/TBV Ratio | 84.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.68
| Current Ratio | 1.68 |
| Quick Ratio | 1.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -214.58% and return on invested capital (ROIC) is -139.03%.
| Return on Equity (ROE) | -214.58% |
| Return on Assets (ROA) | -73.07% |
| Return on Invested Capital (ROIC) | -139.03% |
| Return on Capital Employed (ROCE) | -317.86% |
| Weighted Average Cost of Capital (WACC) | 2.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.89M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +260.25% in the last 52 weeks. The beta is -0.26, so Nuvectis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | +260.25% |
| 50-Day Moving Average | 19.29 |
| 200-Day Moving Average | 11.09 |
| Relative Strength Index (RSI) | 67.69 |
| Average Volume (20 Days) | 210,328 |
Short Selling Information
The latest short interest is 1.84 million, so 5.66% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short Previous Month | 1.51M |
| Short % of Shares Out | 5.66% |
| Short % of Float | 8.69% |
| Short Ratio (days to cover) | 4.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.87M |
| Pretax Income | -27.85M |
| Net Income | -30.28M |
| EBITDA | n/a |
| EBIT | -28.87M |
| Earnings Per Share (EPS) | -$1.30 |
Balance Sheet
The company has $22.16 million in cash and no debt, with a net cash position of $22.16 million or $0.68 per share.
| Cash & Cash Equivalents | 22.16M |
| Total Debt | n/a |
| Net Cash | 22.16M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 9.08M |
| Book Value Per Share | 0.34 |
| Working Capital | 9.08M |
Cash Flow
| Operating Cash Flow | -19.51M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -19.51M |
| FCF Per Share | -$0.60 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nuvectis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.66% |
| Shareholder Yield | -21.66% |
| Earnings Yield | -3.94% |
| FCF Yield | -2.54% |
Analyst Forecast
The average price target for Nuvectis Pharma is $34.20, which is 45.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.20 |
| Price Target Difference | 45.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |